Phase i Trial of Dose-escalated Whole Liver Irradiation with Hepatic Arterial Fluorodeoxyuridine/Leucovorin and Streptozotocin Followed by Fluorodeoxyuridine/Leucovorin and Chemoembolization for Patients with Neuroendocrine Hepatic Metastases

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 41, Issue 4, 2018, Pages 326-331

  Shilkrut, Mark ^a   Sapir, Eli ^a   Hanasoge, Sheela ^a   Schipper, Matthew J ^a   Normolle, Daniel P ^b   Ben Josef, Edgar ^a   Ensminger, William ^a   Lawrence, Theodore S ^a   Feng, Mary ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

chemoembolization; liver metastases; liver radiotherapy; neuroendocrine tumors; phase I trial

Indexed keywords

FLOXURIDINE; FOLINIC ACID; MITOMYCIN; SOMATOSTATIN DERIVATIVE; STREPTOZOCIN; ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CONTINUOUS INFUSION; DRUG DOSE REDUCTION; DRUG TREATMENT FAILURE; HUMAN; LIVER FUNCTION TEST; LIVER METASTASIS; LIVER PERFUSION; LIVER SCINTISCANNING; NEUROENDOCRINE TUMOR; OVERALL SURVIVAL; RADIATION DOSE ESCALATION; RADIATION DOSE FRACTIONATION; RADIOSENSITIZATION; TREATMENT RESPONSE; CARCINOMA; CLINICAL TRIAL; FEMALE; FOLLOW UP; HEPATIC ARTERY; LIVER TUMOR; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PHASE 1 CLINICAL TRIAL; PROGNOSIS; RADIOTHERAPY DOSAGE; SECONDARY; SURVIVAL RATE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NEUROENDOCRINE; CHEMOEMBOLIZATION, THERAPEUTIC; COMBINED MODALITY THERAPY; FEMALE; FLOXURIDINE; FOLLOW-UP STUDIES; HEPATIC ARTERY; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; RADIOTHERAPY DOSAGE; STREPTOZOCIN; SURVIVAL RATE;

EID: 84958818938     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0000000000000276     Document Type: Article

References (23)

1. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13, 715 carcinoid tumors. Cancer. 2003;97:934-959.
2. Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9:61-72.
3. Sarmiento JM, Que FG. Hepatic surgery for metastases from neuroendocrine tumors. Surg Oncol Clin N Am. 2003;12:231-242.
4. van Vilsteren FG, Baskin-Bey ES, Nagorney DM, et al. Liver transplantation for gastroenteropancreatic neuroendocrine cancers: defining selection criteria to improve survival. Liver Transpl. 2006;12:448-456.
5. Yao KA, Talamonti MS, Nemcek A, et al. Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors. Surgery. 2001;130: 677-682; discussion 682-685.
6. Kim YH, Ajani JA, Carrasco CH, et al. Selective hepatic arterial chemoembolization for liver metastases in patients with carcinoid tumor or islet cell carcinoma. Cancer Invest. 1999;17:474-478.
7. Contessa JN, Griffith KA, Wolff E, et al. Radiotherapy for pancreatic neuroendocrine tumors. Int J Radiat Oncol Biol Phys. 2009;75:1196-1200.
8. McGinn CJ, Robertson JM, Ensminger WD, et al. A phase I/II trial of chemoembolization after hepatic arterial FUDR/LV and whole liver radiotherapy. Cancer Ther. 1998;1:88-95.
9. Gyves JW, Stetson P, Ensminger WD, et al. Hepatic arterial streptozocin: A clinical pharmacologic study in patients with liver tumors. Cancer Drug Deliv. 1983;1:63-68.
10. OQuigley J, Pepe M, Fisher L. Continual reassessment method: A practical design for phase 1 clinical trials in cancer. Biometrics. 1990;46:33-48.
11. Cheung YK, Chappell R. Sequential designs for phase I clinical trials with late-onset toxicities. Biometrics. 2000;56:1177-1182.
12. Dawson LA, Normolle D, Balter JM, et al. Analysis of radiationinduced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys. 2002;53:810-821.
13. Ben-Josef E, Normolle D, Ensminger WD, et al. Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. J Clin Oncol. 2005;23:8739-8747.
14. Paprottka PM, Hoffmann RT, Haug A, et al. Radioembolization of symptomatic, unresectable neuroendocrine hepatic metastases using yttrium-90 microspheres. Cardiovasc Intervent Radiol. 2012;35:334-342.
15. Rinke A, Müller HH, Schade-Brittinger C, et al. Placebocontrolled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID Study Group. J Clin Oncol. 2009;27:4656-4663.
16. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:514-523.
17. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:501-513.
18. Manegold PC, Paringer C, Kulka U, et al. Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer. Clin Cancer Res. 2008;14:892-900.
19. Panzuto F, Rinzivillo M, Fazio N, et al. Real-world study of everolimus in advanced progressive neuroendocrine tumors. Oncologist. 2014;19:966-974.
20. Oh D, Lim DH, Park HC, et al. Early three-dimensional conformal radiotherapy for patients with unresectable hepatocellular carcinoma after incomplete transcatheter arterial chemoembolization: A prospective evaluation of efficacy and toxicity. Am J Clin Oncol. 2010;33:370-375.
21. Koo JE, Kim JH, Lim YS, et al. Combination of transarterial chemoembolization and three-dimensional conformal radiotherapy for hepatocellular carcinoma with inferior vena cava tumor thrombus. Int J Radiat Oncol Biol Phys. 2010;78:180-187.
22. Cao Y, Wang H, Johnson TD, et al. Prediction of liver function by using magnetic resonance-based portal venous perfusion imaging. Int J Radiat Oncol Biol Phys. 2013;85:258-263.
23. Normolle D, Pan C, Ben-Josef E, et al. Adaptive trial of personalized radiotherapy for intrahepatic cancer. Per Med. 2010; 7:197-204.